# Pfizer

Type: Company (PFE)

Source: GetYourBrief — https://getyourbrief.com/entity/pfizer
Canonical HTML page: https://getyourbrief.com/entity/pfizer

## Timeline

- **2030**: SDG Deadline — Target year for reducing neonatal mortality to 12 per 1,000 live births.
- **2027**: Potential Launch — Anticipated commercial availability following regulatory approval and CDC recommendation.
- **2026-Q4**: Regulatory Filing — Expected submission of Biologics License Application (BLA) to the FDA.
- **2026-07-07T20:00:00-04:00**: Press conference — Commissioner Tigani and Deputy Mayor Bozorg hold news conference, confirm no movement and ongoing repairs.
- **2026-07-07T18:00:00-04:00**: Repairs begin, some evacuations lifted — Workers begin shoring damaged columns; residents allowed back into several of the evacuated buildings.
- **2026-07-07T14:00:00-04:00**: Stabilization assessment — Officials conduct floor-by-floor inspection up to the 37th floor; find no additional movement, giving contractors greenlight for emergency shoring.
- **2026-07-07T12:00:00-04:00**: Press Conference — Mayor Mamdani, FDNY Commissioner Bonsignore, Chief Esposito, and Commissioner Tigani brief the media, confirm ongoing instability and drone monitoring.
- **2026-07-07T14:00:00Z**: Building Stabilized, No Movement Detected — DOB Commissioner Tigani announces no further movement after hours of monitoring, lifting some evacuation orders. Risk assessments continue floor-by-floor to determine repair viability.
- **2026-07-07T10:00:00-04:00**: Structural damage identified — Inspectors discover two buckled columns on the 21st and 22nd floors, with sagging between floors 21 and 26.
- **2026-07-07T09:00:00-04:00**: Collapse Zone Established — Officials establish a collapse zone, evacuate the building and nine surrounding structures, and close nearby streets as the building continues to shift.
- **2026-07-07T08:30:00-04:00**: DOB Inspection — Department of Buildings inspectors arrive and observe buckled structural columns, multiple cracks, and sagging floors on the 21st floor.
- **2026-07-07T08:30:00-04:00**: Evacuations ordered — Construction workers and occupants of seven adjacent buildings, including a school with ~400 children, are evacuated as a precaution. Nearby streets closed.
- **2026-07-07T08:00:00-04:00**: FDNY Receives Call — FDNY receives reports of a structural issue at the active construction site and dispatches units.
- **2026-07-07T08:00:00-04:00**: Buckled Columns Discovered, Evacuations Begin — At the former Pfizer HQ conversion site, construction workers spot buckling columns. The fire department is called, and nearby buildings—including a school, diplomatic offices, and hotels—are evacuated.
- **2026-07-07T08:00:00-04:00**: Emergency calls — NYC Fire Department receives reports of falling bricks at the 38-story tower at 235 East 42nd Street; firefighters and building inspectors dispatched.

## Recent coverage (20 stories, network-wide)

### 476,000 Lyme Cases Annually: Will Hunters Embrace a New Vaccine?
2026-08-07 07:55:57 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As Pfizer and Valneva seek approval for a new Lyme disease vaccine, healthcare providers confront the challenge of convincing high-risk, rural hunters—who skew vaccine-hesitant—to embrace immunization amid rising tick-borne illness.
Full story: https://gethealthbrief.com/story/hunters-lyme-vaccine-health-2026

### Pfizer-Valneva Lyme Vaccine Targets 476K Annual Cases, But Uptake Uncertain
2026-08-07 07:55:48 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pfizer and Valneva’s planned regulatory submission for a new Lyme disease vaccine enters a market haunted by the failure of LYMErix and amplified vaccine skepticism, challenging the blockbuster potential of a shot aimed at 476,000 annual U.S. cases.
Full story: https://getbiobrief.com/story/pfizer-valneva-lyme-vaccine-bio-2026

### AZN-BMS $400B Talks: What It Means for Drug Prices and Access
2026-08-02 23:37:50 · Sector: health · Sentiment: Neutral · Impact: 9/10 · Sources: 2

A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-pricing-access

### AstraZeneca, BMS $400B Merger Talk Sparks Pharma M&A Frenzy
2026-08-02 23:37:40 · Sector: finance · Sentiment: Neutral · Impact: 9/10 · Sources: 2

The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
Full story: https://getfinancebrief.com/story/astrazeneca-bms-400b-merger-talks-markets

### AstraZeneca, BMS Eye $400B Union to Build Cancer Powerhouse
2026-08-02 23:37:29 · Sector: bio · Sentiment: Neutral · Impact: 9/10 · Sources: 2

The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Full story: https://getbiobrief.com/story/astrazeneca-bms-oncology-pipeline-merger

### Danish Study of 3M Women: 5 More Contraceptives Tied to Brain Tumor Risk
2026-08-01 18:50:39 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 3

A massive Danish registry study finds that several widely used hormonal contraceptives, not just Depo-Provera, elevate the risk of meningioma. This compels clinicians to revise prescribing practices and patient counseling amid rising litigation.
Full story: https://gethealthbrief.com/story/danish-study-3m-women-contraceptives-brain-tumor

### 3M-Woman Study: 5 Contraceptive Hormones Elevate Meningioma Risk
2026-08-01 18:50:29 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

The Danish Medicines Agency’s real-world evidence analysis implicates drospirenone, desogestrel, gestodene, and others in meningioma development, reshaping the risk-benefit landscape for pharmaceutical manufacturers and future contraceptive R&D.
Full story: https://getbiobrief.com/story/3m-women-contraceptive-hormones-meningioma-risk

### 1,600-Unit Adaptive Reuse Project Evacuated After 2 Columns Buckle
2026-07-27 19:07:40 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 3

A structural failure at the country’s largest office-to-residential conversion forces evacuations and spotlights the urgent need for real-time monitoring tech in adaptive reuse projects.
Full story: https://getproptechbrief.com/story/proptech-manhattan-conversion-evacuation

### Buckled Columns Force Evacuation of 1970s-Era Midtown High-Rise Conversion
2026-07-27 07:18:10 · Sector: proptech · Sentiment: Negative · Impact: 6/10 · Sources: 1

The structural scare at a former Pfizer headquarters undergoing luxury residential conversion exposes the risks in adaptive reuse projects and amplifies the need for IoT-based structural monitoring and digital twin technology in aging buildings.
Full story: https://getproptechbrief.com/story/buckled-columns-conversion-evacuation-proptech

### 11-Floor Addition Buckles 37-Story Tower: A Wake-Up Call for Proptech Monitoring
2026-07-12 05:01:07 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 5

The evacuation of nine buildings after structural failure at a Manhattan office-to-residential conversion underscores the critical role of real-time sensors, digital twins, and AI-driven risk assessment. Proptech solutions could have detected load anomalies earlier, and their absence will now spur regulatory and insurer demands for continuous structural health monitoring in adaptive reuse projects.
Full story: https://getproptechbrief.com/story/proptech-manhattan-vertical-addition-structural-failure

### Pfizer HQ Column Scare Puts Proptech's Role in 1,600-Unit Conversion in Focus
2026-07-11 11:21:36 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The buckling of steel columns at the former Pfizer HQ conversion into 1,600 apartments highlights the structural complexities that proptech solutions—from digital twins to real-time monitoring—are designed to mitigate. Experts say the incident doesn't undermine confidence in adaptive reuse but underscores the need for advanced engineering technology to ensure safety and efficiency.
Full story: https://getproptechbrief.com/story/pfizer-column-buckling-proptech-adaptive-reuse

### 2 Dirt-Cheap Dividend Stocks Yielding 6.5% and 5.8%: PFE and BMY for $1,000
2026-07-08 21:25:08 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

In a market where the S&P 500 yields a paltry 1.4%, Pfizer and Bristol Myers Squibb offer income investors a rare combination of outsized yields and deep value. With forward P/E ratios below 11, these beaten-down pharma giants could re-rate as pipeline successes materialize.
Full story: https://getfinancebrief.com/story/dirt-cheap-dividend-stocks-pfe-bmy-finance

### Pfizer & Bristol Myers: 2 Dirt-Cheap Pharma Stocks Yielding 6%+ for Healthcare Investors
2026-07-08 21:22:01 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pfizer and Bristol Myers Squibb combine high dividend yields with deep healthcare pipelines, offering a compelling income-entry into a sector facing patent cliffs but also rich in innovation. For healthcare investors, the stocks demand a long-term view on drug development amid evolving policy risks.
Full story: https://gethealthbrief.com/story/dirt-cheap-dividend-stocks-pfizer-bristol-myers-healthcare

### How $26.2B Pharma Ad Spend Is Creating a New Vertical SaaS Giant
2026-07-02 05:50:53 · Sector: saas · Sentiment: Positive · Impact: 6/10 · Sources: 3

The pharma industry's pivot to digital is fueling a new class of vertical SaaS platforms that unseat horizontal ad tech. Companies like DeepIntent and Pulsepoint are capitalizing on regulatory complexity to carve out a defensible niche.
Full story: https://getsaasbrief.com/story/pharma-ad-tech-vertical-saas

### Pharma's $26.2B Digital Ad Market Sparks Demand for Compliance-First Ad Tech
2026-07-02 05:50:43 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 3

FDA scrutiny and shifting spending are forcing pharma marketers to adopt specialized platforms. These tools navigate privacy rules while enabling precise targeting, but they fragment the ad tech landscape.
Full story: https://getbiobrief.com/story/pharma-digital-ad-tech-compliance

### Pfizer's 6.9% Yield Masks Pipeline Gaps as GLP-1 Race Intensifies
2026-06-28 01:10:29 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

While Pfizer's huge dividend captivates income investors, healthcare leaders should watch for clinical pipeline shortfalls. The 2025 GLP-1 withdrawal signals reliance on an aging blockbuster portfolio as patents approach expiry.
Full story: https://gethealthbrief.com/story/pfizer-dividend-yield-healthcare-pipeline-risks

### Pfizer's 6.9% Yield vs 1% S&P 500: Income Trap or Turnaround Play?
2026-06-28 01:10:24 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

With a 6.9% yield (vs 1% for the S&P 500) and a 130% payout ratio, Pfizer presents a classic risk-reward scenario for income portfolios. The stock’s 60% decline from 2021 highs prices in significant pessimism, but historical resilience may offer patient investors a favorable entry.
Full story: https://getfinancebrief.com/story/pfizer-dividend-yield-income-investing-analysis

### Pfizer’s R&D Setback: Abandoned GLP-1 Drug Leaves 130% Payout Ratio at Risk
2026-06-28 01:10:18 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pfizer’s 2025 GLP-1 failure underscores a faltering pipeline just as generational patent cliffs approach. The 130% dividend payout ratio highlights the financial strain of recent R&D misses, challenging the biotech giant’s turnaround narrative.
Full story: https://getbiobrief.com/story/pfizer-glp-1-failure-dividend-sustainability-bio

### Hong Kong Attracts $191.5B Amgen for Health Tech Boost
2026-04-21 02:09:05 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Hong Kong's enterprise scheme is drawing major health firms like Amgen and Pfizer, valued at over $191.5 billion combined, to expand operations and drive innovation in biotechnology. This influx could enhance local health IT infrastructure and research capabilities, while also raising questions about regulatory alignment with global health standards. For healthcare professionals, this represents opportunities in clinical advancements and talent development amid increasing regional competition.
Full story: https://gethealthbrief.com/story/hong-kong-health-scheme-impact

### Pfizer's Lyme Vaccine Shows Over 70% Efficacy in Pivotal Phase 3 Trial
2026-03-25 02:03:00 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

Pfizer and Valneva have reported positive Phase 3 results for their Lyme disease vaccine candidate, VLA15, demonstrating an efficacy rate exceeding 70%. This development marks a significant milestone in addressing the growing public health threat of tick-borne illnesses, potentially offering the first preventative vaccine for the disease in over two decades.
Full story: https://getbiobrief.com/story/pfizer-lyme-disease-vaccine-phase-3-results

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.